Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral
intravenous |
| gptkbp:affects |
heart rate
myocardial contractility |
| gptkbp:affiliatedWith |
cardiac glycoside
|
| gptkbp:ATCCode |
C01AA05
|
| gptkbp:brand |
gptkb:digoxin
|
| gptkbp:CASNumber |
20830-75-5
|
| gptkbp:contraindication |
gptkb:ventricular_fibrillation
|
| gptkbp:discoveredIn |
18th century
|
| gptkbp:excretion |
gptkb:kidney
|
| gptkbp:hasMolecularFormula |
C41H64O14
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lanoxin
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:producedBy |
GlaxoSmithKline
|
| gptkbp:PubChem_CID |
2724385
DB00390 |
| gptkbp:sideEffect |
gptkb:arrhythmia
nausea vomiting visual disturbances |
| gptkbp:usedFor |
gptkb:atrial_fibrillation
heart failure |
| gptkbp:bfsParent |
gptkb:digoxin
|
| gptkbp:bfsLayer |
6
|